针对风湿性关节炎介导的扩散性大B细胞淋巴瘤的网络和药物导向和BCL2和HSP90AA1药物重定向方法
K M Tanjida Islam1, Abu Zaffar Shibly1
1Department of Biotechnology and Genetic Engineering, Mawlana Bhashani Science and Technology University, Santosh, Tangail -1902, Bangladesh.
International journal of biological macromolecules
|September 1, 2025
概括
类风湿性关节炎 (RA) 增加了扩散性大B细胞淋巴瘤 (DLBCL) 的风险. 研究人员确定BCL2和HSP90AA1是治疗RA和预防DLBCL的新疗法的关键点.
科学领域:
- 癌症学
- 免疫学
- 计算生物学
背景情况:
- 类风湿性关节炎 (RA) 与扩散型大B细胞淋巴瘤 (DLBCL) 的发病率增加有关.
- 导致RA相关DLBCL和有效治疗的分子机制尚不清楚.
- 需要确定RA和DLBCL的治疗点.
研究的目的:
- 确定类风湿性关节炎和扩散型大B细胞淋巴瘤之间共同的关键分子点.
- 评估现有的FDA批准的药物与这些已识别的目标进行重定位.
- 为治疗RA和预防DLBCL的新疗法提供基础.
主要方法:
- 开发了一种新的GCNConv深度学习管道,用于预测共享RA和DLBCL基因网络中的分子枢纽.
- 通过全面的文献挖掘验证了预测的中心.
- 针对804种经过FDA批准的非专利药物进行了网络和药物监督的虚拟选.
主要成果:
- 确定了86个常见于RA和DLBCL的失调基因.
- 确定BCL2和HSP90AA1是具有高深度学习分数的最重要的分子枢纽.
- 拉帕提尼布,伊特拉科纳,沃里科纳和雷加代诺对BCL2和HSP90AA1具有有前途的抑制潜力,其效果优于现有的药物.
结论:
- 对于同时治疗风湿性关节炎及其相关的扩散性大B细胞淋巴瘤来说,BCL2和HSP90AA1是有前途的治疗点.
- 药物重用确定了潜在的候选药物,如拉帕蒂尼布,伊特拉科纳,沃里科纳和雷加多松,以便进一步调查.
- 这项研究为开发双效疗法提供了数据驱动的基础.
更多相关视频
09:53Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens
Published on: February 6, 2017
11.5K
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
2.9K
相关概念视频
Targets for Drug Action: Overview
7.4K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
7.4K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Structure-Activity Relationships and Drug Design
1.0K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.0K
